Sign In
Buy WXXWY
$8.21
-0.700 (-7.86%)
At Close: Jun 03, 2026
WuXi Biologics Reports Solid 2023 Annual Results
09:53am, Tuesday, 26'th Mar 2024
HONG KONG, March 26, 2024 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organiz
WuXi Biologics Named to CDP 'A List' for Water Security
05:24am, Friday, 22'nd Mar 2024
SHANGHAI , March 22, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognize
WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment
08:00am, Tuesday, 05'th Mar 2024
SHANGHAI , March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized
Hoping For Better Luck, HK Stocks Enter The Year Of The Dragon
02:49am, Thursday, 22'nd Feb 2024
Since its launch in 1969, the Hang Seng has always risen in the dragon years, with gains averaging around 14%. But any rally this time could be hampered by uncertainties over the U.S. presidential ele
WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics
05:00am, Wednesday, 21'st Feb 2024
Named Top-Rated for fourth consecutive year Committed to generating long-term value for all stakeholders SHANGHAI , Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading globa
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland
04:31am, Wednesday, 31'st Jan 2024
- First manufacturing run successful for MFG7 facility at the Ireland site- Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland , Jan
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect
07:30pm, Wednesday, 24'th Jan 2024
- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
07:30pm, Tuesday, 16'th Jan 2024
SHANGHAI , Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent
